Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Type 2 Diabetes with Proteinuria
NCT00913393Phase 2Terminated
- Sponsor
- FibroGen
- Start
- Feb 2009
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pamrevlumab in diabetic nephropathy (DN) (3 arms), sponsored by FibroGen. Primary endpoint: Change from baseline in 24-hour urinary Albumin/Creatinine Ratio at 6 months. Started Feb 2009; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00913393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913393.